Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02570289 | AG-ALMOTRIPTAN | ANGITA PHARMA INC. | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Approved |
| 02570297 | AG-ALMOTRIPTAN | ANGITA PHARMA INC. | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Approved |
| 02424029 | ALMOTRIPTAN | PRO DOC LIMITEE | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02466821 | ALMOTRIPTAN | SANIS HEALTH INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02556022 | JAMP ALMOTRIPTAN | JAMP PHARMA CORPORATION | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Approved |
| 02398443 | MYLAN-ALMOTRIPTAN | MYLAN PHARMACEUTICALS ULC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02398435 | MYLAN-ALMOTRIPTAN | MYLAN PHARMACEUTICALS ULC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Marketed |
| 02405334 | SANDOZ ALMOTRIPTAN | SANDOZ CANADA INCORPORATED | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02434849 | TEVA-ALMOTRIPTAN | TEVA CANADA LIMITED | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02405806 | APO-ALMOTRIPTAN | APOTEX INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Dormant |
| 02405792 | APO-ALMOTRIPTAN | APOTEX INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Dormant |
| 02248129 | AXERT 12.5MG | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Cancelled Post Market |
| 02248128 | AXERT 6.25MG | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Cancelled Post Market |
| 02441411 | PMS-ALMOTRIPTAN | PHARMASCIENCE INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Cancelled Pre Market |